A preclinical study has demonstrated that intratumoral injection of ADU-S100 induced CD8+ T-cell-mediated anti-tumor immunity, and the combination of ADU-S100 with ICIs induced synergistic effects in the expansion of CD8+ T cells and durable eradication of tumors in in vivo mouse tumor models24–26. Here, CD8A is linked to neoplasm.